| Literature DB >> 27147200 |
Eva Falomir1, Ricardo Lucas2, Pablo Peñalver3, Rosa Martí-Centelles1, Alexia Dupont2, Alberto Zafra-Gómez4, Miguel Carda5, Juan C Morales6,7.
Abstract
Resveratrol (RES) is a natural polyphenol with relevant and varied biological activity. However, its low bioavailability and rapid metabolism to its glucuronate and sulfate conjugates has opened a debate on the mechanisms underlying its bioactivity. RES prodrugs are being developed to overcome these problems. We have synthesized a series of RES prodrugs and RES sulfate metabolites (RES-S) and evaluated their biological activities. RES glucosylated prodrugs (RES-Glc) were more cytotoxic in HT-29 and MCF-7 cells than RES itself whereas RES-S showed similar or higher cytotoxicity than RES. VEGF production was decreased by RES-Glc, and RES-disulfate (RES-diS) diminished it even more than RES. Finally, RES-Glc and RES-diS inhibited hTERT gene expression to a higher extent than RES. In conclusion, resveratrol prodrugs are promising candidates as anticancer drugs. In addition, RES-S showed distinct biological activity, thus indicating they are not simply RES reservoirs.Entities:
Keywords: angiogenesis; antiproliferation; cytotoxicity; metabolite; prodrug; resveratrol
Mesh:
Substances:
Year: 2016 PMID: 27147200 DOI: 10.1002/cbic.201600084
Source DB: PubMed Journal: Chembiochem ISSN: 1439-4227 Impact factor: 3.164